Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of GSK1070806 in Healthy Caucasian, Chinese, and Japanese Participants
NCT05590338Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aletekitug in atopic dermatitis (AD) (3 arms), sponsored by GSK. Primary endpoints: Area under the concentration-time curve from time zero extrapolated to infinity, Area under the concentration-time curve from time zero to the last quantifiable time and 2 more. Started Nov 2022; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05590338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590338.